Mr. García has served as the Chief Financial Officer of ALX Oncology since January 2020. Prior to joining, he served as Vice President and Chief Financial Officer from May 2013 until August 2019 and as Acting Chief Accounting Officer from May 2013 until July 2013 at PDL BioPharma, Inc., an acquirer of royalties and pharmaceutical assets. From October 2011 to May 2013, Mr. García served as Chief Financial Officer at BioTime, Inc., a clinical-stage biotechnology company now known as Lineage Cell Therapeutics. He previously served as Chief Financial Officer of six biotechnology and high technology companies, including Marina Biotech, Nanosys, Nuvelo, Novacept, IntraBiotics Pharmaceuticals and Dendreon. Mr. García currently serves as a director at Durect Corporation. Mr. García holds a B.A. in Economics and Sociology from Stanford University and an M.B.A. from the University of California, Los Angeles.